General thoracic and cardiovascular surgery · 2025
Analysis of prognostic factors after pulmonary resection for metastatic breast cancer: a 23-year single-institution retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yoshino Ryusei, Takahashi Kengo, Hatanaka Nozomi, Ito Akane, Ujiie Nanami, Yasuda Shunsuke, Kitada Masahiro
Аннотация
OBJECTIVES: Recent advances in therapeutics have substantially improved breast cancer treatment outcomes. However, data on prognostic factors after surgical resection of pulmonary metastases from breast cancer remain limited.
METHODS: This single-center retrospective study analyzed data from patients with breast cancer who had undergone pulmonary metastasectomy between 2000 and 2023. We reviewed clinical and pathological parameters, including the disease-free interval (DFI), size and number of pulmonary metastases.
RESULTS: This study included 33 patients. The median postoperative survival of breast cancer patients with lung metastasis was 40 (range 4-217) months. According to univariate analysis, hormone receptor-positive breast cancer, pStage I or II breast cancer, lung metastases < 20 mm, hormone receptor-positive lung metastases, absence of other metastases, and DFI ≥ 24 months were significantly associated with better survival. Multivariate analysis identified DFI < 24 months (hazard ratio [HR] 9.520, 95% confidence interval [CI] 2.158-27.070) and tumor size ≥ 20 mm (HR 4.958, 95% CI 1.290-27.550) independently predicted poorer survival; ≥ 2 metastatic lesions showed a non-significant trend toward worse outcomes (HR 3.272, 95% CI 0.913-11.090).
CONCLUSIONS: This study clarified the criteria for pulmonary metastasectomy in patients with breast cancer. Considering subtype changes between the primary tumor and metastases could enable personalized therapies.
METHODS: This single-center retrospective study analyzed data from patients with breast cancer who had undergone pulmonary metastasectomy between 2000 and 2023. We reviewed clinical and pathological parameters, including the disease-free interval (DFI), size and number of pulmonary metastases.
RESULTS: This study included 33 patients. The median postoperative survival of breast cancer patients with lung metastasis was 40 (range 4-217) months. According to univariate analysis, hormone receptor-positive breast cancer, pStage I or II breast cancer, lung metastases < 20 mm, hormone receptor-positive lung metastases, absence of other metastases, and DFI ≥ 24 months were significantly associated with better survival. Multivariate analysis identified DFI < 24 months (hazard ratio [HR] 9.520, 95% confidence interval [CI] 2.158-27.070) and tumor size ≥ 20 mm (HR 4.958, 95% CI 1.290-27.550) independently predicted poorer survival; ≥ 2 metastatic lesions showed a non-significant trend toward worse outcomes (HR 3.272, 95% CI 0.913-11.090).
CONCLUSIONS: This study clarified the criteria for pulmonary metastasectomy in patients with breast cancer. Considering subtype changes between the primary tumor and metastases could enable personalized therapies.